Intelligence · Patents
Patents expiring in 2040
Annual patent cliff calendar for 2040 — US pharmaceutical patents by expiration date.
- Patents
- 134
Quick answer
134 indexed pharmaceutical patents have expiration dates in 2040. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 10660904
Optimizing mifepristone levels for cushing's patients
granted -
US 10668060
Tamper-resistant pharmaceutical compositions of opioids and other drugs
granted -
US 10668082
Vaginal inserted estradiol pharmaceutical compositions and methods
granted -
US 10675271
Clonidine and/or clonidine derivatives for use in the prevention and/or treatment of adverse side effects of chemotherapy
granted -
US 10675246
Orally administrable compositions comprising calcium
granted -
US 10675258
Method of using gamma-hydroxybutyrate compositions for the treatment of disorders
granted -
US 10676498
Processes for the preparation of sofosbuvir and intermediates thereof
granted -
US 10675325
Stable formulations of linaclotide
granted -
US 10675288
Natural combination hormone replacement formulations and therapies
granted -
US 10683499
Compositions and methods for modulating TTR expression
granted -
US 10683501
Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
granted -
US 10689377
KRas G12C inhibitors
granted -
US 10689346
Human plasma kallikrein inhibitors
granted -
US 10688102
Combination treatment for migraine and other pain
granted -
US 10688185
Pharmaceutical compositions comprising meloxicam
granted -
US 10695430
Pharmaceutical compositions comprising meloxicam
granted -
US 10695304
Dosage forms and methods for enantiomerically enriched or pure bupropion
granted -
US 10695308
Inhalation formulations of treprostinil
granted -
US 10695429
Pharmaceutical compositions comprising meloxicam
granted -
US 10702535
Pharmaceutical compositions comprising meloxicam
granted -
US 10702576
Stable formulations of linaclotide
granted -
US 10702602
Pharmaceutical compositions comprising meloxicam
granted -
US 10716793
Treprostinil administration by inhalation
granted -
US 10717764
Therapeutically active compounds and their methods of use
granted -
US 10722583
Pharmaceutical compositions comprising meloxicam
granted -
US 10729696
Pharmaceutical compositions comprising meloxicam
granted -
US 10729720
Peroxide formulations and methods and applicators for using the same
granted -
US 10730835
Thalidomide analogs and methods of use
granted -
US 10729773
Pharmaceutical compositions comprising meloxicam
granted -
US 10729697
Pharmaceutical compositions comprising meloxicam
granted -
US 10729774
Pharmaceutical compositions comprising meloxicam
granted -
US 10736859
Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride
granted -
US 10745413
Commercially viable synthesis of cantharidin and bioactive cantharidin derivatives
granted -
US 10751383
Doses and methods for administering telavancin
granted -
US 10758618
Pharmaceutical compositions comprising meloxicam
granted -
US 10758617
Pharmaceutical compositions comprising meloxicam
granted -
US 10758534
Modulators of cystic fibrosis transmembrane conductance regulator
granted -
US 10772963
Etanercept formulations stabilized with xylitol
granted -
US 10772956
Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab
granted -
US 10772880
Method of treatment with tradipitant
granted -
US 10772897
Method for on-demand contraception
granted -
US 10781450
Antisense molecules and methods for treating pathologies
granted -
US 10781218
Substituted inhibitors of menin-MLL and methods of use
granted -
US 10780165
Pharmaceutical compositions comprising meloxicam
granted -
US 10780097
Use of cortisol in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients
granted -
US 10780166
Pharmaceutical compositions comprising meloxicam
granted -
US 10786501
Treatment of prostate cancer
granted -
US 10793547
Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
granted
Frequently asked questions
How many pharma patents expire in 2040?
134 published patents in our USPTO index have expiration dates falling in calendar year 2040.